Lilly(Eli) & Co

NYSE:LLY   3:59:59 PM EDT
236.69
-1.17 (-0.49%)
4:30:09 PM EDT: $236.72 +0.03 (+0.01%)
Other Pre-Announcement

Lilly Highlights Innovation-Based Growth Strategy And Pipeline Developments Announces 2022 Financial Guidance

Published: 12/15/2021 14:39 GMT
Lilly(Eli) & Co (LLY) - Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting.
Eli Lilly - Expects 2022 Revenue to Be Between $27.8 Billion and $28.3 Billion.
Eli Lilly - Sees 2021 EPS to Be in Range of $6.18 to $6.23 on a Reported Basis and $8.15 to $8.20 on a Non-GAAP Basis.
Eli Lilly - Expects 2022 Operating Margin to Be About 30 Percent on a Reported Basis and About 32 Percent on a Non-GAAP Basis.
Eli Lilly - Expects 2022 Earnings per Share to Be in Range of $8.00 to $8.15 on a Reported Basis and $8.50 to $8.65 on a Non-GAAP Basis.
Eli Lilly - Now Expects 2021 Revenue to Be Between $28.0 Billion and $28.3 Billion.
Eli Lilly- on Track to Meet Its Goal of Launching 20 New Medicines Over 10-year Period From 2014 to 2023.
Eli Lilly - Co's Novel Weekly Insulin is on Track to Progress to Phase 3 Studies in 2022.
FY2021 Earnings per Share View $8.02, Revenue View $27.63 Billion -- Refinitiv Ibes Data (analyst estimates).
FY2022 Earnings per Share View $8.18, Revenue View $27.78 Billion -- Refinitiv Ibes Data (analyst estimates).
Eli Lilly - Plans to Initiate Additional Tirzepatide Studies That Include Phase 3 Studies in Obesity Related Outcomes & Obstructive Sleep Apnea.
Eli Lilly- Plans to Initiate Phase 2 Mechanism of Action Study in Kidney Disease.
Eli Lilly- Initiated a Rolling Submission to FDA for Pirtobrutinib.
Eli Lilly- Intends to Initiate a Phase 3 Study to Evaluate Earlier Treatment of Prostate Cancer in Mid-2022.